Since the FDA recently signed the Safety and Innovation Act, which will expedite pediatric drug approval, more pharmaceutical companies are taking pediatric pharmacology and drug development into more consideration. Pharmaceutical companies are maximizing their pre-clinical results from pharmacology studies and are able to more effectively create new treatment methods through pharmacokinetics, pharmacodynamics, and PBPK modeling. There has also been a push to encourage international collaboration with other pharmaceutical companies to engage in pediatric disease research and exchange information globally.
The marcusevans 3rd Pediatric Pharmacology Conference will provide delegates with a comprehensive view of the pediatric pharmacology industry, focusing on the effects that conducting pre-clinical and clinical research have on creating a PK profile. By having this unique profile, the ability of modeling adult data to children will be more easily attained and can be utilized in pediatric drug development and formulation.
Attending This Conference Will Enable You To:
1. Review current pediatric regulations within the FDA and EMA
2. Create effective pre-clinical pharmacology research
3. Model adult data to be effective in pediatric patients
4.Assess innovative specialized models for pediatrics and neonatal patients
5. Overcome pediatric drug formulation, delivery and palatability challenges
Industry leaders attending this conference will benefit from a dynamic presentation format consisting of workshops, panel discussions, and industry-specific case studies that provide accurate, real-world knowledge. Attendees will experience highly interactive conference sessions, 10-15 minutes of Q&A time after each presentation, 4+ hours of networking, and exclusive online access to materials post-event.
What People Are Saying About marcusevans Conferences:
“Very well organized meeting. Excellent presentations by experts in the fields.” – AsubioPharmaceuticals
“Up to date, stimulation and interactive meeting. Enthusiastic audience and high quality speakers.”– Shire Pharmaceuticals “Great in depth coverage of hot topics in an intimate setting that lent itself to excellent discussions.” – Novartis